Literature DB >> 35587282

Glutamatergic dysfunction is associated with phenotypes of VGF-overexpressing mice.

Takahiro Mizoguchi1, Honoka Fujimori1, Takuya Ohba1, Masamitsu Shimazawa2, Shinsuke Nakamura1, Masakazu Shinohara3,4, Hideaki Hara1.   

Abstract

VGF nerve growth factor inducible (VGF) is a neuropeptide precursor, which is induced by several neurotrophic factors, including nerve growth factor and brain-derived neurotrophic factor. Clinically, an upregulation of VGF levels has been reported in the cerebrospinal fluid and prefrontal cortex of patients with schizophrenia. In our previous study, mice overexpressing VGF exhibited schizophrenia-related behaviors. In the current study, we characterized the biochemical changes in the brains of VGF-overexpressing mice. Metabolomics analysis of neurotransmitters revealed that glutamic acid and N-acetyl-L-aspartic acid were increased in the striatum of VGF-overexpressing mice. Additionally, the present study revealed that MK-801, which causes the disturbance in glutamic acid metabolism, increased the expression level of VGF-derived peptide (NAPP129, named VGF20), and VGF-overexpressing mice had higher sensitivity to MK-801. These results suggest that VGF may modulate the regulation of glutamic acid levels and the degree of glutamic acid signaling.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Glutamic acid; MK-801; Schizophrenia; VGF nerve growth factor inducible

Mesh:

Substances:

Year:  2022        PMID: 35587282     DOI: 10.1007/s00221-022-06384-w

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   2.064


  46 in total

1.  Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists.

Authors:  Elena H Chartoff; Carrie L Heusner; Richard D Palmiter
Journal:  Neuropsychopharmacology       Date:  2005-07       Impact factor: 7.853

2.  Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Rafael Favila; Sylvana Stephano; David Mamo; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2011-04-20       Impact factor: 7.853

3.  The neurotrophin-inducible gene Vgf regulates hippocampal function and behavior through a brain-derived neurotrophic factor-dependent mechanism.

Authors:  Ozlem Bozdagi; Erin Rich; Sophie Tronel; Masato Sadahiro; Kamara Patterson; Matthew L Shapiro; Cristina M Alberini; George W Huntley; Stephen R J Salton
Journal:  J Neurosci       Date:  2008-09-24       Impact factor: 6.167

Review 4.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

5.  [Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study].

Authors:  Camilo de la Fuente-Sandoval; Rafael Favila; Patricia Alvarado; Pablo León-Ortiz; Leonardo Díaz-Galvis; Carmen Amezcua; Erik García-Muñoz; Ariel Graff-Guerrero
Journal:  Gac Med Mex       Date:  2009 Mar-Apr       Impact factor: 0.302

6.  Regulation of excitatory amino acid release by N-methyl-D-aspartate receptors in rat striatum: in vivo microdialysis studies.

Authors:  G Bustos; J Abarca; M I Forray; K Gysling; C W Bradberry; R H Roth
Journal:  Brain Res       Date:  1992-07-10       Impact factor: 3.252

7.  Pharmacological blockade of serotonin 5-HT₇ receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission.

Authors:  Pascal Bonaventure; Leah Aluisio; James Shoblock; Jamin D Boggs; Ian C Fraser; Brian Lord; Timothy W Lovenberg; Ruggero Galici
Journal:  PLoS One       Date:  2011-06-20       Impact factor: 3.240

8.  Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex.

Authors:  Leah Aluisio; Ian Fraser; Tamara Berdyyeva; Volha Tryputsen; Brock T Shireman; James Shoblock; Timothy Lovenberg; Christine Dugovic; Pascal Bonaventure
Journal:  Front Neurosci       Date:  2014-05-20       Impact factor: 4.677

9.  Identification of a receptor for neuropeptide VGF and its role in neuropathic pain.

Authors:  Ya-Chun Chen; Alessandro Pristerá; Mahmood Ayub; Richard S Swanwick; Kersti Karu; Yosuke Hamada; Andrew S C Rice; Kenji Okuse
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

10.  Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801.

Authors:  A M Bygrave; S Masiulis; E Nicholson; M Berkemann; C Barkus; R Sprengel; P J Harrison; D M Kullmann; D M Bannerman; D Kätzel
Journal:  Transl Psychiatry       Date:  2016-04-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.